vs
Cooper Companies (The)（COO）与森萨塔科技（ST）财务数据对比。点击上方公司名可切换其他公司
Cooper Companies (The)的季度营收约是森萨塔科技的1.1倍（$1.1B vs $934.8M），森萨塔科技净利率更高（9.3% vs 7.9%，领先1.4%），Cooper Companies (The)同比增速更快（4.6% vs 2.6%），Cooper Companies (The)自由现金流更多（$149.9M vs $104.6M），过去两年Cooper Companies (The)的营收复合增速更高（6.9% vs -5.0%）
CooperCompanies是总部位于美国加利福尼亚州圣拉蒙的全球医疗设备企业，旗下设有两大业务单元：主营隐形眼镜生产的库博光学，以及面向女性健康市场提供医疗设备、生育及基因组相关产品的库博外科。
森萨塔科技控股有限公司是全球领先的工业科技企业，主营传感器、电气保护及控制解决方案的研发、生产与销售，产品覆盖汽车、工业、航空航天、暖通空调、电信等多个下游领域，服务全球制造类企业客户。
COO vs ST — 直观对比
营收规模更大
COO
是对方的1.1倍
$934.8M
营收增速更快
COO
高出2.0%
2.6%
净利率更高
ST
高出1.4%
7.9%
自由现金流更多
COO
多$45.3M
$104.6M
两年增速更快
COO
近两年复合增速
-5.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $934.8M |
| 净利润 | $84.6M | $87.1M |
| 毛利率 | 61.1% | 30.6% |
| 营业利润率 | 13.2% | 15.1% |
| 净利率 | 7.9% | 9.3% |
| 营收同比 | 4.6% | 2.6% |
| 净利润同比 | -28.0% | 24.6% |
| 每股收益（稀释后） | $0.42 | $0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收COOST
| Q1 26 | — | $934.8M | ||
| Q4 25 | $1.1B | $917.9M | ||
| Q3 25 | $1.1B | $932.0M | ||
| Q2 25 | $1.0B | $943.4M | ||
| Q1 25 | $964.7M | $911.3M | ||
| Q4 24 | $1.0B | $907.7M | ||
| Q3 24 | $1.0B | $982.8M | ||
| Q2 24 | $942.6M | $1.0B |
净利润COOST
| Q1 26 | — | $87.1M | ||
| Q4 25 | $84.6M | $63.2M | ||
| Q3 25 | $98.3M | $-162.5M | ||
| Q2 25 | $87.7M | $60.7M | ||
| Q1 25 | $104.3M | $69.9M | ||
| Q4 24 | $117.5M | $5.8M | ||
| Q3 24 | $104.7M | $-25.0M | ||
| Q2 24 | $88.9M | $71.7M |
毛利率COOST
| Q1 26 | — | 30.6% | ||
| Q4 25 | 61.1% | 29.0% | ||
| Q3 25 | 65.3% | 27.8% | ||
| Q2 25 | 67.8% | 30.3% | ||
| Q1 25 | 68.4% | 29.9% | ||
| Q4 24 | 66.5% | 27.1% | ||
| Q3 24 | 66.1% | 28.6% | ||
| Q2 24 | 67.0% | 30.0% |
营业利润率COOST
| Q1 26 | — | 15.1% | ||
| Q4 25 | 13.2% | 10.9% | ||
| Q3 25 | 16.6% | -13.2% | ||
| Q2 25 | 18.4% | 14.6% | ||
| Q1 25 | 18.9% | 13.4% | ||
| Q4 24 | 19.5% | 8.1% | ||
| Q3 24 | 19.2% | -20.3% | ||
| Q2 24 | 17.2% | 12.5% |
净利率COOST
| Q1 26 | — | 9.3% | ||
| Q4 25 | 7.9% | 6.9% | ||
| Q3 25 | 9.3% | -17.4% | ||
| Q2 25 | 8.7% | 6.4% | ||
| Q1 25 | 10.8% | 7.7% | ||
| Q4 24 | 11.5% | 0.6% | ||
| Q3 24 | 10.4% | -2.5% | ||
| Q2 24 | 9.4% | 6.9% |
每股收益（稀释后）COOST
| Q1 26 | — | $0.59 | ||
| Q4 25 | $0.42 | $0.45 | ||
| Q3 25 | $0.49 | $-1.12 | ||
| Q2 25 | $0.44 | $0.41 | ||
| Q1 25 | $0.52 | $0.47 | ||
| Q4 24 | $0.59 | $0.05 | ||
| Q3 24 | $0.52 | $-0.17 | ||
| Q2 24 | $0.44 | $0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $110.6M | $635.1M |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $8.2B | $2.9B |
| 总资产 | $12.4B | $6.8B |
| 负债/权益比越低杠杆越低 | 0.30× | — |
8季度趋势，按日历期对齐
现金及短期投资COOST
| Q1 26 | — | $635.1M | ||
| Q4 25 | $110.6M | $573.0M | ||
| Q3 25 | $124.9M | $791.3M | ||
| Q2 25 | $116.2M | $661.8M | ||
| Q1 25 | $100.9M | $588.1M | ||
| Q4 24 | $107.6M | $593.7M | ||
| Q3 24 | $109.7M | $506.2M | ||
| Q2 24 | $112.4M | $1.0B |
总债务COOST
| Q1 26 | — | — | ||
| Q4 25 | $2.5B | $2.8B | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.6B | $3.2B | ||
| Q3 24 | $2.6B | — | ||
| Q2 24 | $2.7B | — |
股东权益COOST
| Q1 26 | — | $2.9B | ||
| Q4 25 | $8.2B | $2.8B | ||
| Q3 25 | $8.4B | $2.7B | ||
| Q2 25 | $8.3B | $2.9B | ||
| Q1 25 | $8.1B | $2.8B | ||
| Q4 24 | $8.1B | $2.9B | ||
| Q3 24 | $7.9B | $3.0B | ||
| Q2 24 | $7.8B | $3.0B |
总资产COOST
| Q1 26 | — | $6.8B | ||
| Q4 25 | $12.4B | $6.8B | ||
| Q3 25 | $12.4B | $7.1B | ||
| Q2 25 | $12.4B | $7.3B | ||
| Q1 25 | $12.2B | $7.2B | ||
| Q4 24 | $12.3B | $7.1B | ||
| Q3 24 | $12.1B | $7.3B | ||
| Q2 24 | $12.0B | $8.2B |
负债/权益比COOST
| Q1 26 | — | — | ||
| Q4 25 | 0.30× | 1.02× | ||
| Q3 25 | 0.29× | — | ||
| Q2 25 | 0.30× | — | ||
| Q1 25 | 0.31× | — | ||
| Q4 24 | 0.32× | 1.11× | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 0.34× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $247.9M | $122.5M |
| 自由现金流经营现金流 - 资本支出 | $149.9M | $104.6M |
| 自由现金流率自由现金流/营收 | 14.1% | 11.2% |
| 资本支出强度资本支出/营收 | 9.2% | — |
| 现金转化率经营现金流/净利润 | 2.93× | 1.41× |
| 过去12个月自由现金流最近4个季度 | $433.7M | $508.3M |
8季度趋势，按日历期对齐
经营现金流COOST
| Q1 26 | — | $122.5M | ||
| Q4 25 | $247.9M | $201.5M | ||
| Q3 25 | $261.4M | $159.9M | ||
| Q2 25 | $96.2M | $140.9M | ||
| Q1 25 | $190.6M | $119.2M | ||
| Q4 24 | $268.1M | $170.7M | ||
| Q3 24 | $207.5M | $130.9M | ||
| Q2 24 | $111.0M | $143.5M |
自由现金流COOST
| Q1 26 | — | $104.6M | ||
| Q4 25 | $149.9M | $151.9M | ||
| Q3 25 | $164.5M | $136.2M | ||
| Q2 25 | $18.1M | $115.5M | ||
| Q1 25 | $101.2M | $86.6M | ||
| Q4 24 | $128.1M | $138.9M | ||
| Q3 24 | $118.5M | $91.3M | ||
| Q2 24 | $36.9M | $98.4M |
自由现金流率COOST
| Q1 26 | — | 11.2% | ||
| Q4 25 | 14.1% | 16.6% | ||
| Q3 25 | 15.5% | 14.6% | ||
| Q2 25 | 1.8% | 12.2% | ||
| Q1 25 | 10.5% | 9.5% | ||
| Q4 24 | 12.6% | 15.3% | ||
| Q3 24 | 11.8% | 9.3% | ||
| Q2 24 | 3.9% | 9.5% |
资本支出强度COOST
| Q1 26 | — | — | ||
| Q4 25 | 9.2% | 5.4% | ||
| Q3 25 | 9.1% | 2.5% | ||
| Q2 25 | 7.8% | 2.7% | ||
| Q1 25 | 9.3% | 3.6% | ||
| Q4 24 | 13.7% | 3.5% | ||
| Q3 24 | 8.9% | 4.0% | ||
| Q2 24 | 7.9% | 4.4% |
现金转化率COOST
| Q1 26 | — | 1.41× | ||
| Q4 25 | 2.93× | 3.19× | ||
| Q3 25 | 2.66× | — | ||
| Q2 25 | 1.10× | 2.32× | ||
| Q1 25 | 1.83× | 1.70× | ||
| Q4 24 | 2.28× | 29.50× | ||
| Q3 24 | 1.98× | — | ||
| Q2 24 | 1.25× | 2.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
COO
| Sphere Other | $365.0M | 34% |
| Toric And Multifocal | $344.7M | 32% |
| Office And Surgical | $214.5M | 20% |
| Fertility | $140.9M | 13% |
ST
暂无分部数据
